Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint)

D. Cella; M. Bookman; K. Dahl Steffensen; R. L. Coleman; M. Dinh; N. Khandelwal; K. Benjamin; R. Kamalakar; D. Sullivan; L. Floden; S. Hudgens

doi:10.1016/j.annonc.2020.08.948

Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint)

D. Cella
, M. Bookman
, K. Dahl Steffensen
, R. L. Coleman
, M. Dinh
, N. Khandelwal
, K. Benjamin
, R. Kamalakar
, D. Sullivan
, L. Floden
, S. Hudgens

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	809MO
Journal	Annals of Oncology
Volume	31
Issue number	Suppl. 4
Pages (from-to)	S612
Number of pages	1
ISSN	0923-7534
DOIs	https://doi.org/10.1016/j.annonc.2020.08.948
Publication status	Published - 1 Sept 2020
Externally published	Yes
Event	ESMO Virtual Congress - Duration: 19 Sept 2020 → 18 Oct 2020

Conference

Conference	ESMO Virtual Congress
Period	19/09/2020 → 18/10/2020

Access to Document

10.1016/j.annonc.2020.08.948

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Cella, D., Bookman, M., Steffensen, K. D., Coleman, R. L., Dinh, M., Khandelwal, N., Benjamin, K., Kamalakar, R., Sullivan, D., Floden, L., & Hudgens, S. (2020). Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint). Annals of Oncology, 31(Suppl. 4), S612. Article 809MO. https://doi.org/10.1016/j.annonc.2020.08.948

@article{16c31bdad01448f5a9bdd54a2f129d1d,

title = "Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint)",

author = "D. Cella and M. Bookman and Steffensen, \{K. Dahl\} and Coleman, \{R. L.\} and M. Dinh and N. Khandelwal and K. Benjamin and R. Kamalakar and D. Sullivan and L. Floden and S. Hudgens",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2020.08.948",

language = "English",

volume = "31",

pages = "S612",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl. 4",

note = "ESMO Virtual Congress ; Conference date: 19-09-2020 Through 18-10-2020",

}

Cella, D, Bookman, M, Steffensen, KD, Coleman, RL, Dinh, M, Khandelwal, N, Benjamin, K, Kamalakar, R, Sullivan, D, Floden, L & Hudgens, S 2020, 'Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint)', Annals of Oncology, vol. 31, no. Suppl. 4, 809MO, pp. S612. https://doi.org/10.1016/j.annonc.2020.08.948

Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint). / Cella, D.; Bookman, M.; Steffensen, K. Dahl et al.
In: Annals of Oncology, Vol. 31, No. Suppl. 4, 809MO, 01.09.2020, p. S612.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint)

AU - Cella, D.

AU - Bookman, M.

AU - Steffensen, K. Dahl

AU - Coleman, R. L.

AU - Dinh, M.

AU - Khandelwal, N.

AU - Benjamin, K.

AU - Kamalakar, R.

AU - Sullivan, D.

AU - Floden, L.

AU - Hudgens, S.

PY - 2020/9/1

Y1 - 2020/9/1

U2 - 10.1016/j.annonc.2020.08.948

DO - 10.1016/j.annonc.2020.08.948

M3 - Conference abstract in journal

SN - 0923-7534

VL - 31

SP - S612

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 4

M1 - 809MO

T2 - ESMO Virtual Congress

Y2 - 19 September 2020 through 18 October 2020

ER -